VistaGen Therapeutics, Inc. Q3 2026 Earnings Recap

VTGN Q3 2026 February 13, 2026

Get alerts when VTGN reports next quarter

Vistagen Therapeutics reported significant progress in its clinical-stage programs, highlighted by the completion of the PALISADE-3 Phase III trial and continued advancements in its women's health product candidate, refisolone.

Earnings Per Share Beat

$-0.45 vs $-0.51 est.

+11.8% surprise

Revenue Miss

303000 vs 364433 est.

-16.9% surprise

Market Reaction

1-Day -7.23%

5-Day -5.38%

30-Day +12.11%

See VTGN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed the randomized portion of the PALISADE-3 Phase III trial focused on social anxiety disorder, with ongoing enhancements for the PALISADE-4 trial.
Received USAN adoption for refisolone, a hormone-free treatment candidate for menopause-related symptoms, with an IND submission planned for H1 2026.
Cash position stands at $61.8 million, supported by company-wide cash preservation measures to ensure operational efficiency and strategic flexibility.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit VTGN on AllInvestView.